Cabotegravir/rilpivirine - Johnson & Johnson Innovative Medicine/ViiV Healthcare
Alternative Names: CAB LA + RPV LA combination therapy; CABENUVA; Cabotegravir and rilpivirine extended release injectable suspensions; Cabotegravir plus rilpivirine combination therapy; GSK 1265744 plus rilpivirine combination therapy; GSK 1265744 plus TMC 278 combination therapy; Long-acting cabotegravir plus long-acting rilpivirine combination therapyLatest Information Update: 06 May 2024
At a glance
- Originator Janssen Pharmaceuticals; ViiV Healthcare
- Developer GSK; Johnson & Johnson Innovative Medicine; National Institute of Allergy and Infectious Diseases; ViiV Healthcare
- Class Antiretrovirals; Benzonitrile; Fluorobenzenes; Nitriles; Oxazoles; Pyrazines; Pyridones; Pyrimidines; Small molecules
- Mechanism of Action HIV integrase inhibitors; Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 06 May 2024 Launched for HIV-1 infections (Treatment-experienced) in USA (IM)
- 06 Mar 2024 Efficacy and adverse events data from the phase III LATITUDE trial in HIV-1 infections were released by ViiV Healthcare
- 03 Mar 2024 Efficacy data from the phase IIIb SOLAR trial in HIV-1 infections presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024 (CROI-2024)